long term glp-1 drugs fail to provide key long-term health benefit, study shows What helps maximize the long-term

By delaying the rate at which food leaves the stomach and enters the small intestine, GLP-1 effectively moderates the speed at which nutrients are exposed to digestive enzymes

This demonstrates a robust stress-protective effect of DSIP

Many patients experience slower progress after nine to twelve months of therapy, although timing varies depending on adherence, dose optimization, and underlying metabolic conditions

Most GI side effects peak during dose escalation phases and improve within 2 to 4 weeks at a stable dose

Upon activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK), berberine enhances insulin sensitivity, reduces hepatic glucose output, and has been shown in animal models to increase GLP-1 secretion, although this mechanism has not yet been confirmed in large human trials